• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Galecto Inc.

    3/19/25 4:30:45 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLTO alert in real time by email
    S-8 1 glto-20250319.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 19, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

    GALECTO, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

    37-1957007

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification Number)

     

    75 State Street, Suite 100

    Boston, Massachusetts, 02109

    Ole Maaloes Vej 3

    DK-2200 Copenhagen N

    Denmark

    (+45) 70 70 52 10

    (Address of Principal Executive Offices)

    Galecto, Inc. 2020 Equity Incentive Plan

     

    (Full Title of the Plans)

    The Corporation Trust Company

    c/o Galecto, Inc.

    1209 Orange Street

    Wilmington, DC 19801

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    William Hicks, Esq.

    Daniel Bagliebter, Esq.

    Nishant Dharia, Esq.

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

    One Financial Center

    Boston, MA 02111

    (617) 542-6000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     


     

     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 registers 65,849 additional shares of common stock, $0.00001 par value per share, of Galecto, Inc. (the “Registrant”), under the Registrant’s 2020 Equity Incentive Plan (the “2020 Plan”), representing an automatic increase of 65,849 shares reserved under the 2020 Plan effective January 1, 2025 pursuant to the provisions of the 2020 Plan. This registration statement registers additional securities of the same class as other securities for which registration statements filed on Form S-8 on November 4, 2020 (File No. 333-249852), March 29, 2021 (File No. 333-254805), March 9, 2023 (File No. 333-270380) and March 8, 2024 (File No. 333-277792) relating to an employee benefit plan are effective (collectively, the “Prior Registration Statements”). The information contained in the Prior Registration Statements is hereby incorporated by reference pursuant to General Instruction E of Form S-8.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8.

    Exhibits.

    EXHIBIT INDEX

     

     

     

    Exhibit

    No.

    Description

    4.1

    Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as filed with the Commission on November 4, 2020 (File No. 001-39655)).

     

     

    4.2

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on September 5, 2024 (File No. 001-39655)).

     

     

     

    4.3

     

    Certificate of Designation: Series A Non-Voting Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, as filed with the Commission on October 7, 2024 (File No. 001-39655).

     

     

     

    4.4

    Amended and Restated By-laws (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, as filed with the Commission on November 4, 2020 (File No. 001-39655)).

     

     

    4.5

     

    Certificate of Amendment to Amended and Restated By-laws of the Registrant (Incorporated by reference to Exhibit 3.5 to the Registrant's Annual Report on Form 10-K, as filed with the Commission on March 19, 2025 (File No. 001-39655).

     

     

     

    5.1*

    Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

     

     

    23.1*

    Consent of EY Godkendt Revisionspartnerselskab, Independent Registered Public Accounting Firm.

     

     

    23.2*

    Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).

     

     

    24.1*

    Power of Attorney (included on signature page to this registration statement).

     

     

    99.1+

    2020 Equity Incentive Plan and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant’s Annual Report on Form 10-K, as filed with the Commission on March 8, 2024).

     

     

     

    107*

     

    Filing fee table.

     

    +

    Denotes management contract or compensatory plan or arrangement.

    *

    Filed herewith.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Copenhagen, Denmark, on the 19th day of March, 2025.

     

     

    Galecto, Inc.

    Date: March 19, 2025

    By:

    /s/ Hans T. Schambye, M.D., Ph.D.

    Hans T. Schambye, M.D., Ph.D.

    Chief Executive Officer and President

     

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints Hans T. Schambye and Lori Firmani, and each of them, either of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated below.

     

     

     

     

     

    Name

    Title

    Date

     

     

     

    /s/ Hans T. Schambye, M.D., Ph.D.

    Hans T. Schambye, M.D., Ph.D.

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

    March 19, 2025

     

     

     

    /s/ Lori Firmani

    Lori Firmani

    Interim Chief Financial Officer (Principal

    Financial Officer and Accounting Officer)

    March 19, 2025

     

     

     

    /s/ Carl Goldfischer, M.D

    Carl Goldfischer, M.D.

    Chairman

    March 19, 2025

     

     

     

    /s/ Jayson Dallas, M.D.

     

    Director

     

    March 19, 2025

    Jayson Dallas, M.D.

     

     

     

     

     

     

     

     

     

    /s/ Amit D. Munshi

    Amit D. Munshi

    Director

    March 19, 2025

     

     

     

    /s/ Anne Prener, M.D., Ph.D.

    Anne Prener, M.D., Ph.D.

    Director

    March 19, 2025

     

     

     

    /s/ David Shapiro, M.D.

    David Shapiro, M.D.

    Director

    March 19, 2025

     

     

     

    /s/ Amy Wechsler, M.D.

    Amy Wechsler, M.D.

    Director

    March 19, 2025

     


    Get the next $GLTO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GLTO

    DatePrice TargetRatingAnalyst
    8/6/2021$12.00 → $7.00Outperform
    Credit Suisse
    More analyst ratings